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Abstract
Uropathogenic Escherichia coli (UPEC), a leading cause of urinary tract infections, is 
associated with prostate and bladder cancers. Cytotoxic necrotizing factor 1 (CNF1) 
is a key UPEC toxin; however, its role in bladder cancer is unknown. In the present 
study, we found CNF1 induced bladder cancer cells to secrete vascular endothelial 
growth factor (VEGF) through activating Ras homolog family member C (RhoC), 
leading to subsequent angiogenesis in the bladder cancer microenvironment. We 
then investigated that CNF1-mediated RhoC activation modulated the stabilization 
of hypoxia-inducible factor 1α (HIF1α) to upregulate the VEGF. We demonstrated in 
vitro that active RhoC increased heat shock factor 1 (HSF1) phosphorylation, which 
induced the heat shock protein 90α (HSP90α) expression, leading to stabilization of 
HIF1α. Active RhoC elevated HSP90α, HIF1α, VEGF expression, and angiogenesis 
in the human bladder cancer xenografts. In addition, HSP90α, HIF1α, and VEGF 
expression were also found positively correlated with the human bladder cancer de-
velopment. These results provide a potential mechanism through which UPEC con-
tributes to bladder cancer progression, and may provide potential therapeutic targets 
for bladder cancer.
K E Y W O R D S
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1 |  INTRODUCTION
Uropathogenic Escherichia coli (UPEC)-induced urinary 
tract infections (UTIs) usually evoke cystitis, pyelonephri-
tis, and prostatitis.1-3 In addition, UPEC was also reported 
to accelerate the prostate cancer progression in the genet-
ically engineered Hi-Myc mouse prostate cancer model, 
and increase the risk of bladder cancer through promot-
ing CDKN2A methylation.4,5 Previously, we reported 
that cytotoxic necrotizing factor 1 (CNF1), a key UPEC 
toxin, promoted migration and invasion of prostate can-
cer cells and prostate cancer metastasis by activating the 
Cdc42-PAK1 Axis.6 Although UPEC frequently infects 
bladder, the role of CNF1 in bladder cancer has not been 
reported.
CNF1 binds to cells through a specific receptor, enters 
the cytosol, and then activates the Rho GTPases (including 
RhoA, Cdc42, and Rac1) by deamidation of specific gluta-
mine residues.7 RhoA, RhoB, and RhoC belong to the same 
subfamily of Rho GTPases based on phylogenetic analysis,8 
and the expression or activity of RhoA and RhoC are in-
creased in many types of human tumors.9,10 RhoC has been 
reported to facilitate the invasion and metastasis of tumor 
cells11 and promote the tumor angiogenesis by inducing 
the release of vascular endothelial growth factor (VEGF).12 
However, the mechanism by which RhoC induces VEGF is 
unclear.
Angiogenesis is essential for tumor progression and is 
highly dependent on VEGF,13 which is expressed by most 
of the malignant tumors.14,15 Under hypoxic conditions, hy-
poxia-inducible factor 1 (HIF1) induces the transcription of 
VEGF.16 HIF1 is a heterodimeric transcription factor com-
posed of a constitutively expressed HIF1β-subunit and an 
O2-regulated HIF1α subunit, and is a major regulator of an-
giogenesis in the tumor microenvironment.17,18
Under normoxic conditions, HIF1α can be hydroxylated 
at critical proline residues by dioxygenase prolyl hydroxy-
lases, and degraded through pVHL-mediated ubiquitin-pro-
teasome pathway.19,20 However, under hypoxic conditions, 
the activity of dioxygenase prolyl hydroxylases is suppressed, 
and HIF1α is stable.21 In addition, HIF1α degradation can 
be decreased by several pVHL-independent mechanisms.22,23 
For example, the heat shock protein 90 (HSP90), a molecular 
chaperone, has been reported to stabilize HIF1α by binding 
it directly.22 The role and mechanism of RhoC in regulating 
HIF1α has not been reported.
In this study, we examined if and how CNF1 facilitated 
VEGF secretion by tumor cells and the subsequent angio-
genesis in the bladder cancer microenvironment. We found 
that CNF1 induced VEGF and angiogenesis through RhoC-
dependent activation of the HSF1-HSP90α-HIF1α axis. 
These results may provide potential bladder cancer therapeu-
tic targets.
2 |  MATERIALS AND METHODS
2.1 | Cell lines
The T24, 5637, UMUC3, and 293T cells were obtained 
from the ATCC (Manassas, VA, USA). The HUVECs were 
a generous gift from Dr Zhi-Song Zhang from the College of 
Pharmacy, Nankai University, Tianjin, China. For hypoxic 
conditions, the cells were cultured in a modular incubator 
chamber flushed with mixed gas consisting of 1% O2, 5% 
CO2, and 94% N2 at 37°C for normoxic conditions, mixed 
gas consisting of 20% O2, 5% CO2, and 75% N2 at 37°C 
was used. Other reagents used included the HSF1 inhibitor 
KRIBB11 (S8402; Selleck Chemicals, Houston, TX, USA); 
the NF-κB inhibitor BAY 11-7085 (HY-10257; MedChem 
Express, Monmouth Junction, NJ, USA); and the protea-
some inhibitor MG132 (M7449; Sigma-Aldrich, St. Louis, 
MO, USA).
2.2 | Plasmids
The cnf1 gene from UPEC strains 11 was amplified by 
PCR and cloned into pET-28a(+) (Novagen, Madison, 
WI, USA). The coding sequences for RhoC, HIF1α, and 
HSP90α were subcloned into pCMV-Tag2B (Stratagene, 
La Jolla, CA, USA), pLVX-EF1α-IRES-Puro, pLVX-
IRES-Hyg (Clontech, Mountain View, CA, USA) or 
pCDNA3.1-HA-Hygro (Invitrogen, Carlsbad, CA, USA). 
The constructed plasmids and primer sequences are listed 
in Tables S1 and S2.
2.3 | CNF1 recombinant protein 
expression and purification
Recombinant proteins of CNF1 and its mutant C866S were 
expressed, purified, and identified as described previously.6
2.4 | Mutagenesis
Mutagenesis of cnf1 and RhoC was performed using a Fast 
Mutagenesis System kit (TransGen Biotech, Beijing, China) 
according to the manufacturer's protocol. The primers used 
for mutation are listed in Table S2.
2.5 | Transwell migration and 
invasion assays
Cell migration and invasion assays were performed using 
Transwell chambers (pore size 8 μm, Costar, Corning 3422), 
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with Corning Matrigel Matrix (Corning Incorporated, 
Corning, NY, USA) for invasion assays. Cells (1 × 105 in 
200  μL) resuspended in serum-free RPMI 1640 medium 
were added to the upper chamber of uncoated (for migration 
assays) or Matrigel-coated (for invasion assays) membranes 
with PBS, CNF1 (1 nmol/L), or C866S (1 nmol/L). Then, 
600 μL of medium containing 20% fetal bovine serum with 
according PBS, CNF1 (1 nmol/L), or C866S (1 nmol/L) was 
added to the lower chamber. After 12 hours (migration as-
says) or 24 hours (invasion assays) incubation at 37 ℃ in 
a 5% CO2 humidified atmosphere, the cells that adhered to 
the bottom surface of the inserts were fixed in 4% paraform-
aldehyde for 1  hour, and stained with 0.1% crystal violet 
(Beijing Solarbio Science & Technology Co. Ltd., Beijing, 
China) for 15  minutes. Finally, the filters were washed 
three times in PBS and images were captured under a mi-
croscope (Leica Microsystems, Wetzlar, Germany) at 200× 
magnification.
2.6 | Gelatin zymography assay
The activities of MMP2 and MMP9 were analyzed by gelatin 
zymography as described previously.24 In brief, cells were 
incubated with serum-free medium supplemented with PBS 
or CNF1 (1 nmol/L) for 24 hours at 37°C. The conditioned 
medium was collected and mixed with β-mercaptoethanol-
free sample loading buffer without boiling, and then elec-
trophoresed on 10% (w/v) SDS-PAGE containing 0.1% 
(w/v) gelatin (Sigma- Aldrich). After electrophoresis, the 
gels were washed for 30  minutes with 2.5% (v/v) Triton 
X-100 (Merck Millipore, Billerica, MA, USA) to remove 
SDS and then incubated overnight at 37°C in developing 
buffer (50 mmol/L Tris, pH 7.8, 5 mmol/L CaCl2). Bands 
corresponding to the enzyme were visualized by staining 
with 0.2% (w/v) Coomassie brilliant blue R-250 (Merck 
Millipore), 50% (v/v) methanol, and 10% (v/v) acetic acid. 
The activities of MMP2 and MMP9 were quantified using 
ImageJ and β-Actin was detected using western immunob-
lotting as an internal control.
2.7 | ELISA assay
Human bladder cancer cells were seeded in 12-well cul-
ture plates and incubated with serum-free medium supple-
mented with PBS, CNF1 (3 nmol/L), or CNF1 mutant C866S 
(3 nmol/L) for the indicated times at 37°C under normoxic or 
hypoxic conditions. The medium was removed and stored at 
–80°C until the assay was performed. VEGF in the medium 
was assayed using the Human VEGF Mini ABTS ELISA 
Development Kit (PeproTech, Rocky Hill, NJ, USA), ac-
cording to the manufacturer's instructions.
2.8 | Tube formation assay
T24 and 5637 cells were cultured in serum-free RPMI 1640 
supplemented with PBS or CNF1 (3 nmol/L) for 36 hours. 
The conditioned media were collected separately, centri-
fuged, and stored at –80°C Growth factor-reduced Matrigel 
(BD Biosciences, Bedford, MA, USA) was dissolved at 4°C 
and 96-well plates were prepared with 50 μL of matrigel in 
each well after coating and incubating at 37°C for 1  hour. 
HUVECs (1 × 104) were suspended in 100 μL of conditioned 
medium. After 6 hours of incubation at 37°C, HUVECs tube 
formation was assessed using a photomicroscope, and each 
well was photographed at 100× magnification under a light 
microscope. The total length of the tubes was analyzed using 
the ImageJ software.
2.9 | RNA isolation and qRT-PCR
Total RNA was isolated using the TRIzol reagent (Beijing 
Solarbio Science & Technology Co. Ltd.). Total RNA (2 μg) 
was used to synthesize first-strand cDNA using M-MuLV 
reverse transcriptase (Thermo Fisher Scientific, Waltham, 
MA, USA). qRT-PCR was then performed using the SYBR 
green mix (Thermo Fisher Scientific). The reactions were 
performed with a LightCycler 96 Real-Time PCR System 
(Roche, Basel, Switzerland). β-Actin was used as the endoge-
nous control gene and the data were normalized based on the 
transcription level of β-Actin in the wild type and quantified 
using the comparative critical threshold cycle 2-∆∆Ct method. 
The primers used are listed in Table S2.
2.10 | RNA sequencing
After transfection with the vector or RhoC-Q63E, total RNA 
of T24 cells was extracted using the TRIzol reagent. The 
RNA sequencing (RNA-Seq) was performed by Majorbio 
(Shanghai, China). The data were analyzed on the free on-
line platform of Majorbio I-Sanger Cloud Platform (www.i-
sanger.com). The RNA-seq data are available under GEO 
accession GSE129295.
2.11 | Antibodies and western blotting
Antibodies were ordered from the following companies: 
anti-HIF1α (20960-1-AP, 1:1000), anti-HSF1 (51034-1-
AP, 1:1000), anti-RhoC (10632-1-AP, 1:1000), and anti-
Myc (60003-2-Ig, 1:2000) were from Proteintech (Chicago, 
IL,USA); anti-HSF1 phosphorylated at Ser326 antibody 
(ab76076, 1:2000) was from Abcam (Cambridge, MA, USA); 
anti-HA (#3724, 1:1000), and anti-HSP90α (#8165, 1:1000) 
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were from Cell Signaling Technology (Danvers, MA, USA); 
anti-RhoA (ARH04, 1:500) and anti-Rac1 (ARC03, 1:500) 
were from Cytoskeleton (Denver, CO, USA); anti-RhoB (sc-
8048, 1:500) was from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA); anti-Cdc42 (BA2442, 1:500) was from Wuhan 
Boster Biological Technology Co. Ltd. (Wuhan, China); and 
anti-Flag (F1804, 1:1000) was from Sigma-Aldrich. Cells were 
washed with PBS three times after treatment. Whole cell lysates 
were prepared using RIPA lysis buffer (Merck Millipore), 
with the addition of complete protease inhibitors (Roche). The 
protein concentration was determined using the BCA Protein 
Assay Kit (Thermo Fisher Scientific) and approximately 20 μg 
of cell lysates were used. Antibody binding was revealed using 
an HRP-conjugated anti-rabbit IgG or anti-mouse IgG (Sigma-
Aldrich). Antibody complexes were detected using Immobilon 
Western Chemiluminescent HRP Substrate (Merck Millipore) 
and exposed in a Tanon-5200 machine.
2.12 | Immunoprecipitation
Cells were lysed using lysis buffer containing 50  mmol/L 
Tris, pH 7.4, 150  mmol/L NaCl, 0.2  mmol/L EDTA, 1% 
NP-40, and protease inhibitors (Roche). The lysates were 
centrifuged at 14 000  rpm for 15 min at 4°C. The extracts 
were incubated with Anti-c-Myc Agarose (Sigma-Aldrich) 
overnight at 4°C. The beads were then washed exhaustively 
with the lysis buffer. Immobilized proteins were eluted with 
2 × Laemmli sample buffer and subjected to SDS-PAGE.
2.13 | RNA interference
Double-stranded RNAs as siRNAs for the targeted genes and 
scrambled siRNA (siScr) were synthesized by GenePharma 
(Shanghai, China). The sequences (sense strand) of the siR-
NAs are listed in Table S2. Specific gene knockdowns were 
assessed by western blotting. Transfection of siRNAs was 
carried out using Lipofectamine 3000 (Invitrogen).
2.14 | Rho GTPase activation assays
T24 cells were seeded in 10-cm dishes. After treatment, 
RhoC activation was measured using a Rho Activation Assay 
Biochem Kit (BK036, Cytoskeleton) according to the manu-
facturer's protocol.
2.15 | Transduction and transfection
T24 cells stably expressing RhoC constitutively active mu-
tant Q63E were constructed using lentiviral supernatant. 
T24 cells were transiently transfected with the RhoC-
related plasmids using Lipofectamine 3000 (Invitrogen). 
293T cells were transiently transfected with the RhoC, 
HIF1α, and HSP90α-related plasmids using PEI (Sigma- 
Aldrich).
2.16 | Xenograft model
All animal studies were reviewed and approved by the 
Animal Care and Use Committee at Tianjin Medical 
University, Tianjin, China. We made every effort to mini-
mize animal suffering and to reduce the number of ani-
mals used. Six- to eight-week-old female athymic BALB/c 
nude mice were purchased from the Academy of Military 
Medical Science (Beijing, China). T24 cells expressing 
RhoC mutant Q63E or the control were resuspended in 
100 μL of PBS and injected into the flank of the nude mice 
(1 × 106 cells per animal). The xenografts were measured 
as described in figure legends. Then the tumor was col-
lected and the volume and weight were measured. The tu-
mors were fixed in 10% formalin or OCT compound for 
further analysis.
2.17 | Immunohistochemistry
Tumor samples were fixed in 10% formalin for 24  hours 
and processed for paraffin embedding. Sections (5 μm) were 
used for H&E and Immunohistochemistry (IHC) staining for 
RhoC (1:400, 10632-1-AP; Proteintech), HSP90α (1:300, 
13171-1-AP; Proteintech), HIF1α (1:500, ab51608; Abcam), 
VEGF (1:300, 19003-1-AP; Proteintech). Images were ac-
quired using an optical microscope (BX46, Olympus, Tokyo, 
Japan).
2.18 | Tissue microarray analysis
The bladder cancer tissue microarray (BL2081c) containing 
183 samples (eight of normal bladder tissue, eight of adjacent 
normal bladder tissues, and 167 malignant tissues with grade 
I, II, or III) was purchased from Alenabio (Xi'an, China). The 
staining intensity values were determined by Image-Pro Plus 
software.
2.19 | Immunofluorescence 
analysis of tissues
Tumor samples were embedded in OCT compound with 
liquid nitrogen. Frozen sections (5 μm) were used for im-
munofluorescence staining for CD31 (1:300, 550274; BD 
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Biosciences) overnight at 4°C. After that, coverslips were 
washed with PBS, and incubated with FITC-labeled sec-
ondary antibody for 1  hour. Finally tissue sections were 
counterstained with DAPI for nuclei visualization. Images 
were acquired under a fluorescence microscope (IX73, 
Olympus).
2.20 | Statistical analyses
The statistical significance of the differences between groups 
were calculated using the two-tailed Student's t test, non-
parametric Mann-Whitney test, or ANOVA using SPSS 22.0 
software (IBM Corp., Armonk, NY, USA).
3 |  RESULTS
3.1 | CNF1 promotes the migration and 
invasion of bladder cancer cells and vascular 
endothelial cells in vitro
We first examined the effects of CNF1 on the migration 
and invasion abilities of bladder cancer cells. We puri-
fied and validated CNF1 and C866S (an inactive mutant 
of CNF1) recombinant proteins from UPEC strain as we 
previously described,6 and treated bladder cancer cell lines 
5637 and T24. The Transwell assay showed that wild-type 
CNF1 markedly enhanced the migration and invasion of 
T24 and 5637 cells. (Figure  1A,B, Figure  S1A,B). The 
F I G U R E  1  CNF1 promotes the migration and invasion of bladder cancer cells and vascular endothelial cells. Transwell-based migration and 
invasion assays of T24 cells (A,B) and HUVECs (D, E) treated with 1 nmol/L recombinant CNF1 protein, PBS, and the inactivated CNF1 mutant 
C866S (n = 3, three independent experiments). C, Zymography assay of MMP2 activities in 5637 cells treated with PBS and 1 nmol/L CNF1 
(n = 3, three independent experiments). β-Actin was loaded as an internal control. Data are the mean ± SD. *P < .05, **P < .01; one-way ANOVA 
(A, B, D, and E) or Student's t test (C). Scale bar = 50 μm
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gelatinases (MMP2 and MMP9) play a pivotal role in de-
grading the extracellular matrix (ECM).25 Accordingly, 
we explored whether the increased invasive effect could 
be attributed to MMP2 or MMP9 using a gelatin zymog-
raphy assay. The results showed that MMP2 activity was 
increased in 5637 cells treated with CNF1 (Figure  1C), 
and MMP9 activity was not detected in 5637 cells. Both 
MMP2 and MMP9 activity were not detected in T24 cells 
(data not shown). We further validated the effects of CNF1 
on another bladder cancer cell line (UMUC3), which indi-
cated that CNF1 enhanced MMP9 but not MMP2 activity 
(Figure S1C). Taken together, these results provide strong 
evidence that CNF1 promotes the migration and invasion 
of bladder cancer cells and that MMPs may contribute to 
this activity.
Endothelial cells are an important component of the mi-
croenvironment; therefore, we examined the impact of CNF1 
on motility and invasiveness of human umbilical vein vas-
cular endothelial cells (HUVECs). We found CNF1 pro-
moted migration and invasion of HUVECs (Figure  1D,E). 
Therefore, we speculated that CNF1 might have a synergistic 
effect on both the cancer cells and angiogenesis.
3.2 | CNF1 induces VEGF secretion 
in bladder cancer cells and subsequently 
promotes angiogenesis in HUVECs
VEGF is closely associated with tumor angiogenesis,26 and 
tumor cells are one of the main producers of VEGF in the 
tumor microenvironment. In addition, tissue hypoxia is a 
common feature of solid tumors.27 To determine whether 
CNF1 could promote VEGF production from bladder cancer 
cells, we treated T24 or 5637 cells with CNF1, and deter-
mined VEGF secretion under normoxic and hypoxic con-
ditions. CNF1 significantly promoted the VEGF secretion 
from T24 and 5637 cells under hypoxic conditions, but not 
under normoxic conditions (Figure 2A, Figure S2A). CNF1 
promoted VEGF secretion in a time- and concentration-
dependent manner in T24 and 5637 cells (Figure  2B,C, 
Figure S2B,C).
Angiogenesis mainly involves the endothelial cell migra-
tion and tube formation to form new blood vessels.28 Thus, 
we next examined whether CNF1-induced VEGF secretion 
stimulated angiogenesis in a HUVEC model in vitro. The 
results demonstrated that conditioned medium (CM) from 
CNF1-treated T24 and 5637 cells dramatically enhanced 
the tube formation of HUVECs (Figure  2D, Figure  S2D). 
However, CNF1 did not play a direct role in promoting angio-
genesis by itself (Figure S2E). These data suggest that CNF1 
promotes angiogenesis by inducing the VEGF secretion in 
bladder cancer cells.
3.3 | Involvement of HIF1α in  
CNF1-induced VEGF secretion
We next explored the mechanism through which CNF1 
induces the VEGF expression. CNF1 markedly increased 
the VEGF mRNA level in T24 cells by qRT-PCR analy-
sis (Figure 2E). As a pivotal transcription factor, HIF1α is 
critical for VEGF transcription in tumor angiogenesis.29 
Therefore, we investigated the possible effect of CNF1 on 
HIF1α. We treated T24 cells with CNF1 for 24 h and iden-
tified that CNF1 upregulated the HIF1α protein level, but 
not its mRNA expression, compared with that in the con-
trol groups (Figure 2F, Figure S3A). We also ruled out the 
possible role of LPS in inducing HIF1α (Figure  2F). We 
then explored the mechanism by which CNF1 increases the 
protein levels of HIF1α. The addition of the proteasome in-
hibitor MG132 strongly blocked CNF1-mediated HIF1α up-
regulation under hypoxic conditions, suggesting that CNF1 
promotes HIF1α upregulation in a proteasome-dependent 
manner (Figure 2G). In addition, CNF1 effect on VEGF up-
regulation and increased  tube formation of HUVECs were 
not detected in T24 and 5637 cells with HIF1A knockdown 
(Figure  2H-J, Figure  S2F,G). These results suggest that 
CNF1 increases the secretion of VEGF by increasing HIF1α 
accumulation.
3.4 | CNF1 modulates the 
expression of HIF1α and the secretion of 
VEGF by activating RhoC
Rho GTPases are the main targets of CNF1 in mammalian 
cells.30 To determine if Rho GTPase play a role in CNF1-
induced HIF1α upregulation, we knocked down expression 
of several Rho GTPase family members (RhoA, RhoB, 
RhoC, Rac1, and Cdc42) using siRNAs (Figure S3B). The 
CNF1-mediated increase of HIF1α protein levels was sig-
nificantly attenuated by knockdown of RhoC compared 
with that achieved by siScr control, but not by knockdown 
of other Rho GTPases genes (Figure  3A), which suggest 
that CNF1 upregulates HIF1α levels through RhoC. The 
role of RhoC in HIF1α upregulation induced by CNF1 
was verified on another bladder cancer cell line 5637 
(Figure S3C).
We then examined the RhoC activation induced by CNF1. 
Treatment with CNF1 for 3 hours caused a shift in the ap-
parent molecular mass of RhoC on SDS-PAGE (Figure 3B), 
indicating that the RhoC was covalently modified. We further 
validated the immunoblotting results using a pull-down assay 
(Figure 3C). These results suggest that CNF1 can upregulate 
the expression of HIF1α by inducing the RhoC activation in 
bladder cancer cells.
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F I G U R E  2  CNF1 induces VEGF secretion in bladder cancer cells by promoting HIF1α stabilization and subsequently promotes 
angiogenesis. A, The T24 cells were incubated with CNF1 (3 nmol/L) for 24 hours under normoxic or hypoxic conditions, and VEGF secretion 
in the culture medium was analyzed by ELISA (n = 3, three independent experiments). B and C, Time- and concentration-dependent VEGF 
secretion in T24 cells treated by CNF1 (3 nmol/L) under hypoxic conditions (n = 3, three independent experiments). D, The T24 cells were 
stimulated with CNF1 (3 nmol/L) or PBS for 36 hours. The medium was collected and then applied to HUVECs for 6 hours. The capillary-like 
structure formation in HUVECs was examined using a tube formation assay (n = 3, three independent experiments). Tube formation ability was 
visualized and calculated by measuring the length of the tubes. E, T24 cells were incubated with CNF1 (3 nmol/L) for 24 hours under hypoxic 
conditions, and VEGF expression was examined by qPCR (n = 3, three independent experiments). F, Western blotting analysis of HIF1α in T24 
cells after treatment with CNF1 (3 nmol/L) under hypoxic conditions for 24 hours, with PBS, dialysis buffer, LPS (1.26 × 10-3 ng/mL), and C866S 
treatments as controls. G, T24 cells were pretreated with the proteasome inhibitor MG132 (10 μmol/L) for 1 hour followed by stimulation with 
CNF1 (3 nmol/L) for 24 hours under normoxic or hypoxic conditions, and HIF1α expression was analyzed by western blotting. H, Western blotting 
analysis of HIF1α in 3 nmol/L CNF1-treated T24 cells transfected with scrambled or HIF1A siRNA under hypoxic conditions. I, T24 cells were 
transfected with scrambled or HIF1A siRNA for 24 hours followed by stimulation with CNF1 (3 nmol/L) or PBS for 36 hours. VEGF secretion in 
culture medium was examined by ELISA (n = 3, three independent experiments). J, The same medium as described in (I) was applied to HUVECs 
for 6 hours. The capillary-like structure formation in HUVECs was examined using a tube formation assay (n = 3, three independent experiments). 
Data are the mean ± SD. *P < .05, **P < .01; one-way ANOVA (A-C, I and J) or Student's t test (D, E). Scale bar = 100 μm
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To determine the role of active RhoC in the expres-
sion of HIF1α and the secretion of VEGF, wild-type RhoC 
(WT-RhoC, WT) or the constitutively active RhoC mutant 
(CA-RhoC, Q63E; Q63 was deamidated by CNF17) was 
transfected into T24 and 293T cells. Cells transfected with 
CA-RhoC had higher levels of HIF1α and their protein lev-
els were significantly increased in a concentration-dependent 
manner compared with T24 and 293T cells transfected with 
vector or WT-RhoC (Figure  3D, Figure  S3D). However, 
transfection did not significantly increase the mRNA level of 
HIF1α (Figure S3E).
We further analyzed the possible effect of CA-RhoC on 
VEGF secretion. The results confirmed that overexpression 
of CA-RhoC effectively increased the secretion of VEGF 
F I G U R E  3  CNF1 modulates the expression of HIF1α and the secretion of VEGF by activating RhoC in bladder cancer cells. A, T24 cells 
were transfected with a scrambled control siRNA or those targeting respective Rho GTPase siRNAs for 24 hours, followed by stimulation with 
PBS or CNF1 (3 nmol/L) for another 24 hours under hypoxic conditions, and HIF1α expression was examined by western blotting. B, T24 cells 
were incubated with PBS or CNF1 for 3 to 36 hours and mobility-shifting was examined by electrophoresis. C, Western blotting analysis of 
activated RhoC in T24 cells treated with recombinant CNF1 protein (3 nmol/L) or PBS for 24 hours after immunoprecipitation with GTP pull-down 
assays using anti-RhoC antibody. D, Western blotting analysis of T24 cells transfected with vector, wild-type RhoC, or constitutively active RhoC 
(Q63E) under hypoxic conditions. E, T24 cells were transfected with vector, wild-type RhoC, or Q63E for 48 hours, and VEGF secretion in the 
culture medium was examined by ELISA (n = 3, three independent experiments). F, T24 cells were transfected with scrambled or RhoC siRNA 
for 24 hours followed by stimulation with CNF1 protein (3 nmol/L) or PBS for 24 hours, and VEGF secretion in culture medium was examined by 
ELISA (n = 3, three independent experiments). Data are the mean ± SD. *P < .05, **P < .01; one-way ANOVA (E, F)
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compared with that in vector or WT-RhoC groups in T24 and 
5637 cells (Figure 3E, Figure S3F). In addition, transfection 
with RhoC siRNA inhibited the CNF1-enhanced secretion of 
VEGF (Figure 3F).
Taken together, these results indicate that CNF1 enhances 
HIF1α stabilization and VEGF secretion by activating RhoC 
in bladder cancer cells.
3.5 | CNF1-induced RhoC activation 
modulates the stabilization of HIF1α by 
upregulating HSF1-HSP90α
To explore how active RhoC promotes the stabilization of 
HIF1α, we compared the transcriptomes of T24 cells with 
CA-RhoC overexpression or vector control by RNA-Seq. We 
analyzed the genes associated with HIF1α degradation under 
hypoxic conditions (Figure 4A). To verify some of the rel-
evant upregulated genes in the RNA-seq data, qRT-PCR was 
performed (Figure 4B). Among these genes, we found that 
the mRNA level of HSP90AA1 was significantly upregulated 
in CA-RhoC overexpressing cells. Western blotting analysis 
also revealed an increased protein level of HSP90α in CA-
RhoC overexpressing T24 cells (Figure  4C). We further 
validated the effects of CNF1 on HSP90α, which revealed 
that CNF1 also increased HSP90α expression (Figure 4D). 
HSP90 can directly interact with HIF1α and promotes HIF1α 
stabilization under hypoxic conditions,22 which led us to 
examine whether HSP90α is involved in RhoC-facilitated 
HIF1α stabilization. We transfected T24 or 293T cells with 
HA-tagged HSP90α, MYC-tagged HIF1α and FLAG-tagged 
CA-RhoC or vector. Co-IP analysis indicated that CA-RhoC 
enhanced the interaction between HSP90α and HIF1α under 
hypoxic conditions (Figure 4E, Figure S4A).
NF-κB and HSF1 were reported to regulate the expres-
sion of HSP90α.31 Ser326 phosphorylation is important 
for the transcriptional activity of HSF1.31,32 We found in-
creased levels of HSF1 phosphorylated at Ser326, HSP90α, 
and HIF1α after CA-RhoC overexpression (Figure  4F,G) 
or CNF1 treatment (Figure  4H), but there was no change 
in NF-κB activity (Figure  S4B). We blocked HSF1 and 
NF-κB using commercial inhibitors (Figure 4F, Figure S4C) 
and found that enhanced levels of phosphorylated HSF1, 
HSP90α, and HIF1α were attenuated by inhibiting HSF1, 
but not by inhibiting NF-κB. To further confirm the role of 
HSF1 in promoting HSP90α and HIF1α levels, we knocked 
down HSF1 using specific siRNAs, and found that CA-
RhoC or CNF1 induced HSF1 phosphorylation, HSP90α 
and HIF1α increasement were not observed (Figure 4G,H, 
Figure S4D).The effect of HSF1 on HIF1α in 5637 cells was 
also validated (Figure S4E). CNF1 effect on VEGF upreg-
ulation was not detected in T24 and 5637 cells with HSF1 
knockdown (Figure 4I, Figure S4F).
The above results demonstrate that CNF1-induced RhoC 
activation can increase the HIF1α stabilization in bladder 
cancer cells through the HSF1-HSP90α axis.
3.6 | Active RhoC promotes in vivo tumor-
associated angiogenesis of bladder cancer
To determine if the in vitro observations could be replicated 
in vivo, the effect of RhoC activation on the angiogenesis 
mediated by the bladder cancer cells was analyzed in vivo 
using a subcutaneous tumor mouse model. T24 cells were 
transduced with constitutively expressed CA-RhoC or the 
vector control. The expression of RhoC was confirmed in 
the transduced cells, and elevated HSP90α and HIF1α lev-
els were also identified in T24 cells with CA-RhoC over-
expression (Figure  S4G). Five weeks after transplantation, 
we observed significantly the elevated tumor growth in the 
CA-RhoC overexpression group compared with that in the 
control group (Figure 5A,B). The tumor volume and weight 
were 3.6- and 2.4-fold higher than those in the control group 
(Figure 5C,D). In addition, tumors in mice receiving the T24 
cells with CA-RhoC had higher levels of HSP90α, HIF1α, 
and VEGF (Figure 5E-H). We also found increased micro-
vessel density (MVD) in tumors derived from the CA-RhoC-
overexpressing T24 cells compared with those in the control 
group (Figure 5I).
Overall, these results suggest that activation of RhoC by 
CNF1 promotes angiogenesis and tumor growth in vivo.
3.7 | HSP90α, HIF1α, and VEGF are 
implicated in advanced human bladder cancer
To identify the possible clinical correlations to our findings, 
the expression profiles of HSP90α, HIF1α, and VEGF were 
analyzed by IHC staining using human tissue arrays contain-
ing 183 samples including 167 bladder carcinoma tissues 
of grade I, II, or III, eight normal and eight adjacent normal 
bladder tissues. We found that the levels of HSP90α, HIF1α, 
and VEGF were strongly correlated with bladder cancer ad-
vanced grades (Figure 6A-D). Furthermore, the levels of their 
expression were correlated with each other (Figure  6E-G). 
In addition, we performed the analysis using the integrated 
cancer microarray database, Oncomine,33 which revealed 
that HSP90AA1 (Figure 6H) and HIF1A (Figure 6I) mRNA 
levels are markedly upregulated in bladder cancer samples. 
We also analyzed the dataset from The Cancer Genome Atlas 
(TCGA).34 The HSP90AA1 mRNA level (based on 407 blad-
der cancer samples) was significantly higher compared with 
the adjacent normal bladder tissues of 18 bladder cancer sam-
ples, and no difference was observed for HIF1A (Figure 6J,K). 
However, both HSP90AA1 and HIF1A mRNA levels were 
7936 |   GUO et al.
found significantly increased in 18 bladder cancer samples 
compared with their paired adjacent normal bladder tissues 
(Figure 6L,M). Furthermore, we performed the Kaplan-Meier 
survival analysis from the Gene Expression Profiling 
Interactive Analysis (GEPIA) web server.35 Elevated HIF1A 
expression is positively correlated with the poor survival in 
F I G U R E  4  CNF1-induced RhoC activation modulates the HIF1α stabilization by upregulating HSF1- HSP90α interaction. A, Heatmap of 
the HIF1α degradation-related gene expression levels detected by RNA-seq in T24 cells stably expressing the RhoC constitutively active mutant 
Q63E or vector under hypoxic condition. B, qRT-PCR confirmation of the upregulated genes expression profile under hypoxic condition (n = 3, 
three independent experiments). C, Western blotting analysis of T24 cells transduced with vector and Q63E under hypoxic condition. D, Western 
blotting analysis of T24 cells treated with 1 nmol/L CNF1. E, T24 cells were transfected with combinations of MYC-HIF1α, HA-HSP90α, and 
FLAG-RhoC-Q63E under normoxic or hypoxic condition. Protein extracts from the transfected cells were subjected to IP with antibody against 
MYC and analyzed by immunoblotting with the indicated antibodies. F, Analysis of phosphorylated HSF1, total HSF1, HSP90α, and HIF1α in 
transduced T24 cells treated with the HSF1 inhibitor KRIBB11 (10 μmol/L), or with DMSO as the control under hypoxic condition. G and H, 
Western blotting analysis of transduced T24 cells (G) and 1 nmol/L CNF1 treated T24 cells (H) subject to siRNAs targeting HSF1 and scrambled 
non-targeting control siRNA under hypoxic conditions. I, T24 cells were transfected with scrambled or HSF1 siRNA for 24 hours followed by 
stimulation with CNF1 (3 nmol/L) or PBS for 24 hours under hypoxic condition, and VEGF secretion in culture medium was examined by ELISA 
(n = 3, three independent experiments). Data are the mean ± SD. **P < .01; one-way ANOVA (B, I)
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patients with bladder carcinoma, and a trend without statisti-
cal significance was observed for HSP90AA1 (Figure 6N,O). 
We also analyzed published data from the GEO database.36 
Analysis of two published clinical datasets (GSE83586 and 
GSE101723) revealed significantly positive correlations be-
tween the expression of HSP90AA1 and HIF1A in bladder 
cancer (Figure 6P). Taken together, these observations sup-
port that the HSP90α-HIF1α-VEGF axis plays an important 
role in the bladder cancer development.
4 |  DISCUSSION
CNF1 has been reported to activate several Rho GTPases by 
deamidating specific glutamine residues.7 CNF1-mediated 
Rho GTPase activation changes the cell function and con-
tributes to many physiological and pathological processes. 
For example, CNF1 promotes bacterial invasion into host 
cells by activating Rac.37 Previously, we reported that 
CNF1 increased prostate cancer cell migration and invasion 
F I G U R E  5  Active RhoC promotes the tumor-associated angiogenesis of bladder cancer in vivo. A, Morphological images of tumor 
xenografts resected from nude mice injected with T24 cells transduced with vector (VEC) or constitutively active mutant of RhoC (Q63E) 
after 5 weeks in each group. B, Tumor growth in nude mice with Q63E or VEC T24 cells subcutaneously injected into their flanks (n = 9, two 
independent experiments). Tumor volumes were determined by direct measurement using a caliper and calculated using the formula: (widest 
diameter × smallest diameter2)/2. Tumor volume (C) and weight (D) of xenograft nude mice injected with Q63E or VEC T24 cells in the xenograft 
model (n = 9, two independent experiments). E-H, Immunohistochemical analysis of RhoC, HSP90α, HIF1α, or VEGF expression in murine 
tumors. I, Immunofluorescence analysis of CD31+ blood vessels in murine tumors (n = 3, three independent experiments each with multiple fields). 
Data are the mean ± SD. *P < .05, **P < .01; non-parametric Mann-Whitney test (B, C, D and I). Scale bar = 50 μm (E-H) or 100 μm (I)
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F I G U R E  6  HSP90α, HIF1α, and VEGF expressions are positively correlated with advanced human bladder cancer. A, IHC analysis of 
HSP90α, HIF1α, and VEGF using human bladder cancer tissue microarray. Representative images (original magnification 200×) from normal 
bladder tissues, adjacent normal bladder tissues, and malignant bladder tissues at different stages are shown. B-D, Mean intensity of staining 
of HSP90α (B), HIF1α (C), and VEGF (D) were determined by Image-Pro Plus software and presented with box plots. E-G, The correlation 
coefficient and P values were analyzed as indicated. H and I, Analysis of Sanchez-Carbayo bladder from Oncomine for the expression of 
HSP90AA1 (H) and HIF1A (I) in normal human bladder tissues and bladder carcinoma samples. J and K, Analysis of the mRNA level of 
HSP90AA1 (J) and HIF1A (K) in 407 bladder cancer and 18 adjacent normal bladder tissues obtained from the TCGA database. L and M, Analysis 
of TCGA data set for the mRNA expression of HSP90AA1 (L) and HIF1A (M) in 18 bladder cancer samples and the paired adjacent normal 
bladder tissues. N and O, Kaplan-Meier survival analysis for the relationship between the survival of bladder cancer patients and expression 
levels of HSP90AA1 (N) and HIF1A (O) mRNA using the online tool (http://gepia.cance r-pku.cn/). P, Analysis of public datasets (GSE83586, 
GSE101723) for the expression of HIF1A and HSP90AA1 in bladder cancer. The relative levels of HSP90AA1 were plotted against that of HIF1A. 
Data are presented with box plots. *P < .05, **P < .01; one-way ANOVA (B-D); Pearson's correlation coefficient and Spearman's correlation 
coefficient (E-G, P); unpaired, two-tailed Student's t test (H-K); paired, two-tailed Student's t test (L, M) or logrank test (N, O)
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to promote prostate cancer metastasis through activating 
Cdc42,6 and CNF1 reduced macrophage phagocytosis to 
induce inflammation during acute UTIs partially through 
Cdc42.38 Schmidt reported that CNF1 enhanced breast can-
cer cell invasion through activating RhoC.39
RhoC has been reported to play important roles in tumor 
progression, including angiogenesis,40-42 proliferation,43 inva-
sion, and metastasis of tumors.11,44 RhoC has been regarded 
as a new target for therapeutic vaccination against metastatic 
cancer.45 The mRNA and protein levels of RhoC are signifi-
cantly higher in bladder cancer than in normal tissue.46 For 
bladder cancer, previous studies showed that RhoC was in-
volved in its lung colonization,47 and the RhoC/ROCK path-
way was closely associated with its invasion and metastasis.48 
In addition, RhoC is correlated with the angiogenic compo-
nent FGF2 in urothelial cell carcinoma of the bladder.49
RhoC was shown to induce angiogenesis by regulating en-
dothelial cell migration and organization,41 and to maintain 
vascular homeostasis by modulating the endothelial cell pro-
liferation and permeability.42 In addition, reports have shown 
that RhoC increases the VEGF expression.40,50-52 It was re-
ported that p38 is involved in RhoC-induced VEGF produc-
tion in breast cancer cells.52 However, the detailed specific 
mechanism through which RhoC accelerates the VEGF se-
cretion in bladder cancer remains unclear.
HIF1α stabilization is important for VEGF transcription, 
and several mechanisms, in addition to the classical pVHL 
pathway, have been reported to stabilize HIF1α: (1) HSP90 
could directly interact with HIF1α and protect it from deg-
radation22; (2) increased expression of small ubiquitin-like 
modifier SUMO-1 under hypoxic conditions results in HIF1α 
SUMOylation and stabilization53,54; (3) USP20, a deubiq-
uitinase, binds to HIF1α and subsequently removes ubiqui-
tin from HIF1α, leading to its stabilization55; and (4) YY1, 
a transcription factor, can directly bind to and stabilizing 
HIF1α.56 In the present study, we examined the transcription 
of factors associated with HIF1α stabilization and identified 
that activated RhoC induced HIF1α stabilization and VEGF 
production by increasing the HSP90α expression and the in-
teraction between HIF1α and HSP90.
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